BOSTON, Aug. 12 (GenomeWeb News) - MDS Sciex is diversifying its product offerings beyond its flagship line of mass spectrometry instruments to include cellular analysis, the company said at IBC's Drug Discovery Technology conference, held here this week.
MDS Sciex, the analytical instruments division of publicly traded biotech firm MDS, was previewing its newest product, CellKey, at the meeting. A company official told GenomeWeb News' sister publication Cell-Based Assay News that it plans to officially launch the product next month at the Society for Biomolecular Screening conference in
CellKey is a label-free cellular analysis platform based on cellular dielectric spectroscopy. In this technique, cells are grown on electrodes embedded in microwell plates, and a constant low-level voltage is applied. A detection instrument senses changes in electrical impedance that result from changes in cell morphology, confluence, adherence, and interactions.
For further details about the product, MDS Sciex' commercialization plans, and the competitive landscape for this technology, see the Aug. 15 issue of Cell-Based Assay News.